The European Commission approves Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements
investors, but appearances may be deceiving. Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN ) is in my view that sort of stock. Its market ..... a few years hence. This article evaluates REGN using a sum-of-the-parts type of analysis
Regeneron Pharmaceuticals (NASDAQ: REGN ) Q2 2014 Earnings Call August 05, 2014 8:30 am ET Executives Michael Aberman - Vice President of Strategy & Investor Relations
million, and chief scientific officer, George Yancopoulos, received a staggering $81.6 million in 2012. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cancer and inflammation. The
The following audio is from a conference call that will begin on August 05, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc on Tuesday reported quarterly sales above expectations on surging demand for its Eylea treatment for macular degeneration, the leading cause of blindness in the elderly.
Regeneron Pharmaceuticals (NASDAQ: REGN ): Q2 EPS of $2.47 beats by $0.18 . Revenue of $666M (+45.5% Y/Y) beats by $18.01M . Press Release Post your comment!
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday August 4. 4 Charts with Fangs: Google (NASDAQ: GOOG ), (NASDAQ: GOOGL ), Facebook (NASDAQ: FB ), Amazon (NASDAQ: AMZN ), Netflix (NASDAQ: NFLX ) Cramer discussed with technical ...
LIN , LPX , MDU , MGM , MMP , MSI , MWW , MZOR , NILE , NNN , [[NTi]], NVDQ , NWN , ODP , OXF , OZM , PMC , PQ , RBA , REGN , RHP , RIGL , RTI , SCMP , SCOR , SMG , SNSS , SPAR , STE , TDG , VMC , VSI , VTG , WLK , WNR , ZBRA , ZTS 2 comments!
on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday July 30. Bullish Calls: Regeneron (NASDAQ: REGN ), Celgene (NASDAQ: CELG ), Biogen Idec (NASDAQ: BIIB ), Gilead (NASDAQ: GILD ), Seattle Genetics (NASDAQ: SGEN